Comparison of pharmacological intervention needed in the study population by sex and CVD risk category
| Male (n=606) n (%) | Female (n=701) n (%) | P value | |
| Blood pressure-lowering therapy*, n (%) | 0.02 | ||
| Low (<1%) | – | 12 (9.4) | |
| Moderate (1%–5%) | 40 (14.3) | 101 (28.8) | |
| High (>5%) | 99 (30.3) | 86 (38.5) | |
| Statin treatment Ldl_c† | 0.04 | ||
| Low (<1%) | – | 3 (2.3) | |
| Moderate (1%–5%) | 5 (1.8) | 21 (6) | |
| High (>5%) | 6 (1.8) | 5 (2.2) | |
*Defined as having systolic blood pressure of >150 mm Hg based on Eighth Joint National Committee (JNC 8) and the 2013 European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines.
†Defined as having low-density lipoprotein cholesterol (Ldl_c) ≥190 mg/dL based on 2016 Task Force for the Management of Dyslipidaemias of the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines.
CVD, cardiovascular disease.